Sight Sciences, Inc. (SGHT)
| Market Cap | 468.25M +120.2% |
| Revenue (ttm) | 83.38M +9.3% |
| Net Income | -29.76M |
| EPS | -0.56 |
| Shares Out | 55.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 205,280 |
| Open | 8.54 |
| Previous Close | 8.55 |
| Day's Range | 8.30 - 8.57 |
| 52-Week Range | 3.19 - 9.24 |
| Beta | 2.42 |
| Analysts | Buy |
| Price Target | 9.00 (+5.88%) |
| Earnings Date | Aug 5, 2026 |
About SGHT
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and O... [Read more]
Financial Performance
In 2025, Sight Sciences's revenue was $77.36 million, a decrease of -3.13% compared to the previous year's $79.87 million. Losses were -$38.43 million, -25.40% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for SGHT stock is "Buy." The 12-month stock price target is $9.0, which is an increase of 5.88% from the latest price.
News
Sight Sciences announces updated TearCare System Indications for Use
Sight Sciences (SGHT) announced that, effective August 18, the FDA updated the TearCare System Indications for Use to state: “The Sight Sciences TearCare System is a thermal-activated gland expression...
TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease
MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologie...
Sight Sciences price target raised to $8 from $6 at Citi
Citi raised the firm’s price target on Sight Sciences (SGHT) to $8 from $6 and keeps a Neutral rating on the shares. The firm is more optimistic on the medical…
Sight Sciences price target raised to $8 from $7 at UBS
UBS raised the firm’s price target on Sight Sciences (SGHT) to $8 from $7 and keeps a Buy rating on the shares.
Sight Sciences reports Q2 EPS (8c), consensus (14c)
Reports Q2 revenue $23.39M, consensus $21.69M. “We delivered a strong second quarter, with revenue growth accelerating to 20% year-over-year, and both business segments contributing meaningfully to th...
Sight Sciences raises FY26 revenue view to $88M-$92M from $83M-$89M
Consensus $86.08M. The company said, “Sight Sciences (SGHT) raised its revenue guidance for full year 2026 to range from $88 million to $92 million, representing year-over-year growth of 14% to…
Sight Sciences Earnings Call Transcript: Q2 2026
Q2 2026 saw 20% revenue growth, record performance in both interventional segments, and improved margins driven by one-time tariff refunds. Full-year guidance was raised for both revenue and adjusted OpEx, with strong cash discipline and new product launches supporting future growth.
Sight Sciences Earnings release: Q2 2026
Sight Sciences released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Sight Sciences Quarterly report: Q2 2026
Sight Sciences has published its Q2 2026 quarterly earnings report on August 5, 2026.
Sight Sciences Reports Second Quarter 2026 Financial Results
Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance
Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems
MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innov...
Sight Sciences Slides: Investor presentation
Sight Sciences has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Sight Sciences announces FDA clearance of Omni Ultra Surgical System
Sight Sciences (SGHT) announced FDA 510 clearance of the Omni Ultra Surgical System for canaloplasty followed by trabeculotomy for the reduction of intraocular pressure in adult patients with primary ...
Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System
New system expands the Company's leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation. New system expands the Company...
Sight Sciences resumed with a Buy at UBS
UBS resumed coverage of Sight Sciences (SGHT) with a Buy rating with a price target of $7, down from $11. The eyecare sector is healthier than expected, with resilient U.S.
Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026
MENLO PARK, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innov...
Sight Sciences price target raised to $6 from $5.15 at Citi
Citi raised the firm’s price target on Sight Sciences (SGHT) to $6 from $5.15 and keeps a Neutral rating on the shares. For Q2 earnings season, given “the skittish trading…
Sight Sciences Transcript: AGM 2026
The meeting was held virtually, with board and officer introductions, and two proposals presented: re-election of directors and auditor ratification. Both proposals passed, and no questions were submitted by stockholders.
Sight Sciences price target raised to $5.15 from $4.35 at Citi
Citi raised the firm’s price target on Sight Sciences (SGHT) to $5.15 from $4.35 and keeps a Neutral rating on the shares. The firm updated models in the medical technology…
Sight Sciences Transcript: Stifel 2026 Virtual Ophthalmology Forum
Interventional glaucoma is seeing increased adoption and stable growth, with OMNI maintaining leadership and a new OMNI Ultra launch expected. TearCare outperformed expectations in Q1, with higher utilization in reimbursed markets and ongoing efforts to expand coverage. Both segments are positioned for continued growth and market expansion.
Sight Sciences Transcript: Bank of America Global Healthcare Conference 2026
The company is advancing interventional technologies for glaucoma and dry eye, with strong clinical data and payer traction for its TearCare system and robust growth in its OMNI glaucoma business. Both segments are in high-growth mode, supported by a strong pipeline.
Sight Sciences reports Q1 EPS (24c), consensus (20c)
Reports Q1 revenue $19.7M, consensus $18.55M. “We delivered a strong start to 2026, with first quarter results reflecting a return to double-digit revenue growth, sustained gross margin strength, and ...
Sight Sciences raises FY26 revenue view to $83M-$89M from $82M-$88M
Consensus $84.56M. The company said, “Sight Sciences (SGHT) raises its revenue guidance for full year 2026 to range from $83.0 million to $89.0 million, representing growth of 7% to 15%…
Sight Sciences Earnings Call Transcript: Q1 2026
Q1 2026 saw 13% revenue growth, driven by strong performance in both glaucoma and dry eye segments, with raised full-year guidance and improved margins. Patent litigation awarded $55M and ongoing royalties, though subject to appeal. Cash usage improved and no equity raise is anticipated.
Sight Sciences Earnings release: Q1 2026
Sight Sciences released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.